Main Content
Clinical immunomonitoring
The further development of various vaccine platforms is an overarching goal of our work. Existing and new platform technologies are first tested for safety and efficacy in animal models and then in clinical trials. The analysis of the humoral immune response within clinical trials is an important parameter to evaluate the immunogenicity of the vaccine candidate.
For this purpose, standardised and validated methods for the quantification of binding and virus-neutralising antibodies are developed and applied at the Institute of Virology in Marburg. The focus of the work is on the filoviruses Ebolavirus and Marburgvirus, CCHFV, SARS-CoV-2 and MERS-CoV.
Project Lead:
Verena Krähling
Staff members:
Dirk Becker, Gesche Gerresheim, Astrid Herwig, Michael Klüver, Jolanda Mezzacapo, Helena Müller-Kräuter
Funding:
